0001171843-17-007592.txt : 20171211
0001171843-17-007592.hdr.sgml : 20171211
20171211170519
ACCESSION NUMBER: 0001171843-17-007592
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171207
FILED AS OF DATE: 20171211
DATE AS OF CHANGE: 20171211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PEHL MICHAEL F.
CENTRAL INDEX KEY: 0001677939
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 171250149
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNOMEDICS INC
CENTRAL INDEX KEY: 0000722830
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 611009366
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 300 AMERICAN RD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
BUSINESS PHONE: 9736058200
MAIL ADDRESS:
STREET 1: 300 AMERICAN ROAD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
4
1
f4_pehl121117.xml
OWNERSHIP DOCUMENT
X0306
4
2017-12-07
0
0000722830
IMMUNOMEDICS INC
IMMU
0001677939
PEHL MICHAEL F.
C/O IMMUNOMEDICS, INC
300 THE AMERICAN ROAD
MORRIS PLAINS
NJ
07950
0
1
0
0
President and CEO
Stock Options (right to buy)
11.86
2017-12-07
4
A
0
750000
0.0
A
2024-12-07
Common Stock, par value $0.01 per share
750000
750000
D
Stock Options (right to buy)
11.86
2017-12-07
4
A
0
1500000
0.0
A
2024-12-07
Common Stock, par value $0.01 per share
1500000
1500000
D
The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter.
The reporting person was granted performance-based vesting stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options will vest (i) as to 750,000 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant (each date a "Vesting Date") and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $23.72 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date; and (ii) as to 750,000 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $35.58 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date.
To the extent, the performance-based vesting criteria of the stock options is not attained on an applicable Vesting Date, to the extent such performance-based vesting criteria is subsequently attained the tranche of stock options may vest on the date such criteria is met.
/s/ Michael F. Pehl
2017-12-11